Cancer cells generally present a
higher demand for iron,
which
plays crucial roles in tumor progression and metastasis. This iron
addiction provides opportunities to develop broad spectrum anticancer
drugs that target iron metabolism. In this context, prochelation approaches
are investigated to release metal-binding compounds under specific
conditions, thereby limiting off-target toxicity. Here, we demonstrate
a prochelation strategy inspired by the bioreduction of tetrazolium
cations widely employed to assess the viability of mammalian cells.
We designed a series of tetrazolium-based compounds for the intracellular
release of metal-binding formazan ligands. The combination of reduction
potentials appropriate for intracellular reduction and an N-pyridyl donor on the formazan scaffold led to two effective
prochelators. The reduced formazans bind as tridentate ligands and
stabilize low-spin Fe(II) centers in complexes of 2:1 ligand-to-metal
stoichiometry. The tetrazolium salts are stable in blood serum for
over 24 h, and antiproliferative activities at micromolar levels were
recorded in a panel of cancer cell lines. Additional assays confirmed
the intracellular activation of the prochelators and their ability
to affect cell cycle progression, induce apoptotic death, and interfere
with iron availability. Demonstrating the role of iron in their intracellular
effects, the prochelators impacted the expression levels of key iron
regulators (i.e., transferrin receptor 1 and ferritin), and iron supplementation
mitigated their cytotoxicity. Overall, this work introduces the tetrazolium
core as a platform to build prochelators that can be tuned for activation
in the reducing environment of cancer cells and produce antiproliferative
formazan chelators that interfere with cellular iron homeostasis.